Aethlon Medical Initiates Hemopurifier(R) Shipments to India.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has shipped Hemopurifier[R] treatment cartridges to support a clinical study to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India. The study, which will evaluate the safety of the Hemopurifier[R] in ten patients, is expected to commence in the coming month.

The Fortis study reinforces Aethlon's strategy to pursue early treatment and commercialization opportunities in India. Aethlon will focus on viral conditions of greatest concern to Indian citizens, and opportunities that offer treatment access to the Hemopurifier[R] within India's growing medical tourism industry. Targeted conditions may include Dengue Hemorrhagic Fever (DHF), HIV/AIDS, and Hepatitis-C (HCV). Pending the accumulation of further data, Aethlon may also pursue opportunities to implement the Hemopurifier[R] as an adjunct therapy for cancer in the region. Commercialization of the Hemopurifier[R] into the Indian marketplace will be based on obtaining sufficient clinical data to drive practitioner acceptance in the marketplace.

Dr. Vijay Kher, Director of Nephrology at Fortis Hospital, has been named the principal investigator of the study. Previously, Dr. Kher acted as principal investigator of a Hemopurifier[R] study conducted at the Apollo Hospital in Delhi. The Apollo study documented initial safety of the Hemopurifier[R], and provided early efficacy observations during 24-treatments administered to health compromised dialysis patients co-infected with HCV.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device to treat infectious disease. The Hemopurifier[R] addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier[R]are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier[R] in a 24-treatment human study and has received approval to continue further humans studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier[R]as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information on Aethlon Medical and its Hemopurifier[R] technology can be accessed at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.